|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
7.200 USD |
-4.00% | +10.60% | -62.44% | |
Published on 05/31/2025 at 08:20
This article is reserved for members Unlock the article: REGISTER NOW!
© Reuters – 2025
|
UBS Adjusts Price Target on Arvinas to $21 From $74, Maintains Buy Rating |
May. 15 |
MT |
|
Arvinas, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 10:40 AM |
May. 13 |
|
|
Morgan Stanley Cuts Price Target on Arvinas to $11 From $12, Keeps Equalweight Rating |
May. 09 |
MT |
|
Truist Downgrades Arvinas to Hold From Buy, Cuts Price Target to $11 From $21 |
May. 05 |
MT |
|
Jefferies Downgrades Arvinas to Hold From Buy, Adjusts Price Target to $10 From $52 |
May. 02 |
MT |
|
TD Cowen Downgrades Arvinas to Hold From Buy |
May. 02 |
MT |
|
Arvinas Shares Drop; Cancels Two Drug Trials With Pfizer Amid Capital Markets Challenges |
May. 01 |
DJ |
|
Earnings, Data in Focus as US Equity Futures Rise Pre-Bell |
May. 01 |
MT |
|
Arvinas To Reduce Workforce By Approximately 33% – SEC Filing |
May. 01 |
RE |
|
Top Premarket Decliners |
May. 01 |
MT |
|
Arvinas, Inc., Q1 2025 Earnings Call, May 01, 2025 |
May. 01 |
|
|
Arvinas, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 |
May. 01 |
CI |
|
Arvinas, Inc. Presents Data from Preclinical Combination Studies of ARV-393 |
Apr. 28 |
CI |
|
Arvinas Announces Results from the Veritac-2 Trial Selected as Late-Breaking Oral Presentation At the 2025 American Society of Clinical Oncology Annual Meeting |
Apr. 23 |
CI |
|
Truist Slashes Price Target on Arvinas to $21 From $65, Keeps Buy Rating |
Apr. 09 |
MT |
|
Arvinas Says First-in-Human Data for ARV-102 Shows Substantial Reduction of LRRK2 |
Apr. 04 |
MT |
|
Arvinas, Inc. Presents First-In-Human Data for Investigational Oral Protac ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation |
Apr. 04 |
CI |
|
Goldman Sachs Downgrades Arvinas to Neutral From Buy, Cuts Price Target to $15 From $70 |
Mar. 13 |
MT |
|
Arvinas’ Vepdegestrant Likely to Have ‘Restricted Label’ in Breast Cancer, Wedbush Says |
Mar. 12 |
MT |
|
Wedbush Downgrades Arvinas to Neutral From Outperform, Adjusts Price Target to $12 From $57 |
Mar. 12 |
MT |
|
Sector Update: Health Care Stocks Lower in Late Afternoon Trading |
Mar. 11 |
MT |
|
Citigroup Cuts Arvinas’ Price Target to $10 From $19, Maintains Neutral Rating |
Mar. 11 |
MT |
|
Top Midday Decliners |
Mar. 11 |
MT |
|
Sector Update: Health Care Stocks Slide in Afternoon Trading |
Mar. 11 |
MT |
|
Oppenheimer Downgrades Arvinas to Perform From Outperform |
Mar. 11 |
MT |
ARVN: Dynamic Chart
Arvinas, Inc. is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The Company uses its PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It has four investigational clinical-stage programs: vepdegestrant (ARV-471) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-766 and bavdegalutamide for the treatment of men with metastatic castration-resistant prostate cancer, and ARV-102 for the treatment of patients with neurodegenerative disorders. Its product candidate, ARV-393, is designed to target the B-cell lymphoma 6, or BCL6 protein.
More about the company
Buy
Average target price
19.42USD
Spread / Average Target
+169.68%
Consensus
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
